Clinical trials: sponsored by Beijing Tongren Hospital
Primary Open Angle Glaucoma
CRISPR/Cas9 Instantaneous Gene Editing Therapy to Intraocular Hypertensive POAG With MYOC Mutation
This study is intented to evaluate the safety, tolerability and preliminary efficacy of CRISPR/Cas9 Instantaneous Gene Editing Therapy (BD113 virus-like particle, also BD113vLVP) in patients with primary open-angle glaucoma…
- Trial name
- NCT06465537
- Testing
- BD113vVLP
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Shanghai BDgene Co., Ltd.
Sentinel Nodes, Breast Cancer
Technetium Tc 99m Sulfur Colloid Injection for Tracing Sentinel Nodes in Breast Cancer
The aim of the study is a prospective multicentre phase-3 study that aims to evaluate the detection rate of sentinel lymph node in patients with breast cancer.
- Trial name
- NCT07764653
- Testing
- Technetium Tc 99m Sulfur Colloid Injection, Mitoxantrone Hydrochloride Injection for Tracing
- Where
- China
- Volunteers
- 213 people
- Sponsor
- HTA Co., Ltd.
Atrial Fibrillation, Obstructive Sleep Apnea
The Efficacy of PAP Therapy on Reducing AF Recurrence in Patients With Morbidity of OSA
This study aims to test the effectiveness of positive airway pressure therapy on reducing clinical failure after rhythm control treatment and restoring with regular heart beat in atrial fibrillation patients with obstructive…
- Trial name
- AFOSA (NCT04519489)
- Testing
- PAP therapy with telemonitoring, AF standard management and OSA general care
- Where
- 2 sites in China
- Volunteers
- 129 people
- Sponsor
- Philips (China) Investment CO., LTD
Dry Eye Disease (DED)
Phase III Clinical Study of Lifitegrast Ophthalmic Solution for the Treatment of Dry Eye Disease
This study is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical trial designed to evaluate the efficacy and safety of Lifitegrast Ophthalmic Solution.
- Trial name
- NCT06879782
- Where
- China
- Volunteers
- 820 people
- Sponsor
- Lunan Better Pharmaceutical Co., LTD.
Advanced Solid Tumor
A Phase 1 Study of CX1003 (Kanitinib) in Patients with Advanced Solid Tumors
CX1003 is a novel multi-target tyrosine kinase inhibitor that is designed to primarily inhibit vascular endothelial growth factor receptor 2 (VEGFR2) and hepatocyte growth factor receptor (HGFR/MET).
- Trial name
- NCT04093466
- Testing
- CX1003
- Where
- China
- Volunteers
- 126 people
- Sponsor
- Beijing Konruns Pharmaceutical Co., Ltd.
Laryngectomy; Status
Evaluation of the Safety and Efficacy of Voice Prosthesis in Voice Reconstruction After Total Laryngectomy
The objective of the study is to evaluate the clinical safety and efficacy of voice prosthesis for voice reconstruction after total laryngectomy in China.
- Trial name
- NCT05482815
- Testing
- Provox Vega Voice prosthesis
- Where
- 3 sites in China
- Volunteers
- 80 people
- Sponsor
- Atos Medical AB
Leber Congenital Amaurosis, Retinitis Pigmentosa
Treatment of RP and LCA by Primary RPE Transplantation
Early Phase I Study of the Safety and Preliminary Efficacy of Human primary Retinal Pigment Epithelial (HuRPE) Cells Subretinal Transplantation in Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA) Patients
- Trial name
- NCT03566147
- Testing
- Human primary Retinal Pigment Epithelial (HuRPE) cells
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Eyecure Therapeutics Inc.
Type 2 Diabetes
A Phase I Study of 8-week Continuous Treatment With Polyethylene Glycol Loxenatide in Patients With Type 2 Diabetes
Polyethylene Glycol Loxenatide (PEX168) is a new human glucagon-like peptide 1 (GLP-1) analogue that created on the basis of the Exenatide and modified by polyethylene glycol (PEG).
- Trial name
- NCT01976858
- Testing
- PEX168
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Corneal Ulcer
Transplantation of Acellular Corneal Matrix to Treat Corneal Ulcer
This study is to develop a lamellar keratoplasty method for corneal ulcer using acellular corneal matrix (ACM) and to make an analysis among patients for its therapeutic effect.
- Trial name
- NCT01244776
- Testing
- acellular corneal matrix
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shaanxi Aierfu Activtissue Engineering